Discover more from FarmaKology’s Substack
FarmaKology-Promising anti-cancer treatment discovered in sea squirts
Acticor Biotech is a clinical stage biopharmaceutical company, a spin-off from INSERM (French National Institute of Health and Medical Research), which is developing an innovative “first in-class” treatment for cardiovascular emergencies, with a primary focus on Acute Ischemic Stroke.
Sutro Biopharma and Tasly Biopharmaceuticals Enter into Exclusive License Agreement for STRO-002 in Greater China
Sutro Biopharma, Inc., a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced an exclusive license agreement with Tasly Biopharmaceuticals Co., Ltd. for the development and commercialization of STRO-002 in Greater China, consisting of mainland China, Hong Kong, Macau and Taiwan. STRO-002 is a FolRα-targeting antibody-drug conjugate , currently in clinical studies for patients with ovarian and endometrial cancers in the U.S. and Europe.
In a recent revelation, experts have said that antiviral pills against Covid, may not be safe for everyone. After doctors and pharmacists closely analysed the pills, they concluded that these pills can be life-threatening when taken with other medications. The Food and Drug Administration (FDA), recently gave heads up to two pills - Pfizer's Paxlovid and Merck's Molnupiravair. Paxlovid's treatment is a combination of two pills taken over five days. It has been authorised for mild to moderate Covid in people as young as 12 years, who have underlying conditions that increase the risk of hospitalisation and death from the coronavirus.
I-Mab Announces IND Approval from China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combination with Pembrolizumab in Solid Tumors
I-Mab , a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, announced that the Center for Drug Evaluation of China’s National Medical Products Administration has approved I-Mab’s IND submission for the initiation of a phase 2 trial in China for enoblituzumab (also known as TJ271) in combination with pembrolizumab (Keytruda®) in patients with solid tumors, including non-small cell lung cancer , urothelial carcinoma, and other selected cancers. I-Mab has acquired exclusive rights to develop and commercialize enoblituzumab in Greater China from MacroGenics.
Moderna Announces Switzerland Exercises its Option to Purchase Seven Million Additional Doses of Moderna's COVID-19 Booster Vaccine in 2022
Moderna, Inc. , a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Swiss Federal Government has exercised its option to purchase an additional seven million doses of Moderna's booster vaccine for delivery in the second half of 2022. These doses are in addition to the initial seven million doses of booster vaccine the Swiss Federal Government agreed to purchase for delivery in 2022 and brings Switzerland's order commitment to a total of 27.5 million doses.